Clinical Site Services International (CSSi), the leader in global patient enrollment solutions for the clinical research industry, is pleased to announce their new partnership with TruBios.
Clinical Site Services International (CSSi), the leader in global patient enrollment solutions for the clinical research industry, is pleased to announce their new partnership with TruBios. TruBios, based out of Rockville, MD, is the only fully integrated US-based biotechnology services company focused on the Latin American region offering customized clinical research, commercialization, and venture capital solutions. TruBios is also an independent corporate partner of Johns Hopkins University MCC.
Clinical Site Services International (CSSi), a division of CSS, is partnering with TruBios to deliver CROs/Pharma and Biotech clients solutions that are focused on site performance while also allowing CSSi to expand its site network in Latin America. Pharmaceutical/CRO clients will be provided with top sites and the expertise and understanding of patients who are willing to participate in clinical research.
"Continuing to deliver the most innovative and proven enrollment solutions for our clients, whether in the US or abroad, is a challenge we embrace and one that our partnership with TruBios will address as we expand our site network in Latin America," said Chris Trizna, President of CSS. "Working together, CSSi and TruBios will be able to offer insight and knowledge to help sites in Latin America identify potential patients by utilizing enrollment strategies that are appropriate to the sites and local communities."
"Clinical Site Services and TruBios represent an impressive collaboration, as both of our companies are committed to providing innovative solutions to accelerate the development of clinical trials," said Dr. Roberto Trujillo, CEO of TruBios. "The TruBios Research Network (TRN) covers approx. 60% of the countries in Latin America and partnering with CSSi to deliver customized enrollment services will only allow both our companies to grow and expand further in those countries."
CSSi delivers high-performing, qualified sites to CRO and Pharma clients through their proprietary site management solutions. CSS has long recognized that only sites are able to enroll patients but sometimes sites are not able to identify patients from within their own databases. Understanding and recognizing this challenge by developing an individualized recruitment plan for each site, prevents delays in enrollment. By partnering with TruBios, CSSi's Latin America clients will have the ability to use qualified sites that are already identified as high performing research facilities.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.